Tactile Medical (Nasdaq: TCMD) will release first quarter fiscal 2026 results after market close on May 4, 2026. Management will host a conference call and webcast at 5:00 p.m. ET the same day; a replay will be available for two weeks and the webcast will be archived on the investor site.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TCMD
-2.82%
-2.82%Session close to close
In the Apr 21 session, TCMD declined 2.82%, reflecting a moderate negative market reaction.
This announcement sets the timing and access details for Tactile Medical’s Q1 FY 2026 results, with ...
Analysis
This announcement sets the timing and access details for Tactile Medical’s Q1 FY 2026 results, with a conference call at 5:00 p.m. ET on May 4, 2026. It follows the company’s established pattern of pre-announcing earnings dates, as seen before the Q4 and FY 2025 release. Investors may focus on how upcoming results track prior revenue growth, margin trends, and guidance outlined earlier in 2026.
Announced Q4 and FY 2025 results date and conference call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
For prior earnings date guidance on Feb 3, 2026, TCMD saw a modest -2.09% move over the next day, suggesting past reactions to scheduling announcements have been relatively contained.
Recent Company History
Over the last several months, Tactile Medical has paired routine investor communications with solid fundamental updates. The prior earnings date notice on Feb 3, 2026 preceded Q4 and full-year 2025 results and a subsequent -2.09% move. That release ultimately featured strong revenue growth, margin expansion, and 2026 guidance. Today’s announcement similarly sets expectations for the upcoming Q1 FY 2026 release and conference call without providing new financial figures.
"conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary"
Lymphedema is a chronic swelling that happens when the body’s fluid-draining network can’t move fluid away from tissues, causing persistent puffiness, heaviness and sometimes skin changes. Investors pay attention because it represents a steady demand for diagnostics, drugs, devices and long-term care—think of it like a clogged drain that creates ongoing repair and maintenance needs, so new treatments or devices can shift patient outcomes and company revenue for years.
lipedemamedical
"conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary"
Lipedema is a chronic condition where fat deposits build up unevenly under the skin—usually in the legs and sometimes the arms—causing swelling, tenderness and reduced mobility; it is often mistaken for ordinary weight gain. For investors, it matters because the condition creates sustained demand for specialized diagnostics, non‑surgical therapies, compression garments and surgical treatments, as well as ongoing care and reimbursement considerations, making it a distinct market opportunity in medical devices and therapies.
chronic venous insufficiencymedical
"conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary"
A long-term condition in which the one-way valves in leg veins do not work properly, causing blood to pool, swelling, pain, skin changes or ulcers; think of it as a plumbing problem where backflow wears out pipes and fixtures. Investors care because it is a common, chronic market with ongoing demand for treatments, devices and wound-care products, and outcomes depend on clinical data, regulatory approvals and reimbursement decisions that affect revenue streams.
chronic pulmonary diseasemedical
"including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping"
A long-term lung condition that makes breathing harder by narrowing airways or damaging lung tissue, often causing coughing, shortness of breath and reduced exercise ability; think of it as a car with a partially clogged air filter that lowers performance over time. It matters to investors because the condition drives demand for medicines, devices, hospital care and clinical trials, so changes in treatment approvals, market size, or reimbursement can directly affect company revenues and healthcare costs.
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2026 financial results will be released after the market closes on Monday, May 4, 2026.
Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 4, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13759535. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13759535. The webcast will be archived at investors.tactilemedical.com.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Investor Inquiries: Sam Bentzinger Gilmartin Group investorrelations@tactilemedical.com
FAQ
When will Tactile Medical (TCMD) release Q1 FY2026 financial results?
Tactile Medical will release Q1 FY2026 results after the market closes on May 4, 2026. According to the company, management will discuss results on a conference call at 5:00 p.m. Eastern Time that same day and provide a live webcast for investors.
How can I join the Tactile Medical (TCMD) May 4, 2026 earnings call?
Dial 877-407-3088 (201-389-0927 international) and enter access code 13759535 to join the call. According to the company, a live webcast will also be available on the investor relations website for those who prefer an online connection.
Where will the Tactile Medical (TCMD) May 4, 2026 webcast be available?
The webcast will be available at the company's investor relations site, investors.tactilemedical.com. According to the company, the live webcast will be archived on that site after the call for later viewing by investors and analysts.
Will there be a replay of the Tactile Medical (TCMD) May 4, 2026 conference call and how long will it be available?
A replay will be available for two weeks via 877-660-6853 (201-612-7415 international), access code 13759535. According to the company, investors unable to join live can access the replay for 14 days following the call.
What time is the Tactile Medical (TCMD) conference call on May 4, 2026?
The conference call is scheduled for 5:00 p.m. Eastern Time on May 4, 2026. According to the company, management will host a question-and-answer session during the call to discuss the quarter's financial results and developments.
How can investors contact Tactile Medical (TCMD) investor relations regarding the May 4, 2026 results?
Investors can contact investor relations via the provided email investorrelations@tactilemedical.com or reach out to Gilmartin Group representative Sam Bentzinger. According to the company, those contact channels are intended for investor inquiries related to the announcement.
